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0022-2836 © 2012 Elsevier Ltd. Open accSerum IgG is a potent inhibitor of monoclonal antibody (mAb) binding to
the cell-surface Fcγ receptors (FcγRs), which mediate cytotoxic and
phagocytic effector functions. Here, we show that this competition can be
eliminated, selectively, by the introduction to serum of (i) an enzyme that
displaces Fc from FcγRs and (ii) a modiﬁcation present in the therapeutic
mAb that renders it resistant to that enzyme. Speciﬁcally, we show that (i)
EndoS (endoglycosidase S) cleaves only complex-type glycans of the type
found on IgG but (ii) is inactive against an engineered IgG Fc with
oligomannose-type glycans. EndoS thus reduces FcγR binding of serum
IgG, but not that of engineered mAb. Introduction of both the engineered
mAb and endoglycosidase in serum leads to a dramatic increase in FcγR
binding compared to the introduction of mAb in serum alone. Antibody
receptor refocusing is a general technique for boosting the effector signal of
therapeutic antibodies.© 2012 Elsevier Ltd. Open access under CC BY license.The ability of an antibody to recruit the killing
machinery of the cellular immune system is depen-
dent on the interaction between the antibody Fc
domain and Fc receptors found on cells such as
macrophages and natural killer cells.1 This anti-
body-dependent cellular cytotoxicity (ADCC) is
required for the efﬁcient elimination of cancerous
or infected cells. The binding of Fc to Fcγ receptorsresses:
ally to this work.
ody-dependent
tor; mAb, monoclonal
Ab, serum antibody.
ess under CC BY license.(FcγR) bridge the adaptive and innate immune
systems and is a primary focus of therapeutic
monoclonal antibody (mAb) research.2,3
The afﬁnity for each FcγR is different for each
of the naturally occurring isotopes of IgG (IgG1–
4).4 Similarly, artiﬁcial point mutations in the
receptor-binding interface (notably, the lower
hinge and upper loops of the Cγ2 regions) exhibit
a wide range of modiﬁed afﬁnities for both
activating and inhibitory receptors.5 The strength
of Fc:FcγR interaction is also highly dependent on
the presence and composition of the dynamic N-
linked glycans attached to Asn297 of both of the
Cγ2 domains of the IgG Fc homodimer.6–9 For
example, de-fucosylation increases ADCC, princi-
pally by reducing unfavorable steric interactions
between the Fc glycan and the glycan at Asn164
2 Antibody Receptor Refocusingof the activating FcγRIIIa receptor found on
natural killer cells.9–11 One well-explored ap-
proach to enhance effect or function is therefore
to increase the intrinsic afﬁnity for FcγR by
engineering the Fc structure of a given mAb.12
However, an additional factor also impacts Fc:
FcγR interactions: the presence of competing
serum IgG.
Serum antibody (sAb) (50–100 μM) is present in
signiﬁcant excess of the dissociation constant (Kd)
for IgG Fc:FcγR interactions (0.1–10 μM).13,4 TheFig. 1. Endoglycosidase-mediated deactivation of serum Ig
was determined, by ELISA, in the presence of PBS (phospha
serum and detected using a secondary antibody speciﬁc for th
The crystal structure of FcGlcNAc (blue ribbon) overlaid with s
superposition of Cα residues from one protomer while leavin
1H3T, 1H3U, 1H3V, 1H3W, 1H3X, 1H3Y, 2DTQ, 2DTS, 3D
equivalent Cα atoms (Tyr296) in Fc
GlcNAc and naturally g
approximately 8 Å. For crystallographic analysis, FcGlcNAc (S
and was crystallized after 42 days with the use of the sitting-
100 nL precipitant equilibrated against 95 μL reservoirs. Crys
25% (w/v) polyethylene glycol 1500 and 0.100 M SPG System b
cryoprotectant containing the mother liquor diluted in 25%
nitrogen stream. X-ray diffraction data were recorded at beam
Data were processed and scaled using DENZO and SCALEPA
native Fc (PDB accession number 3AVE) as a search model. M
reﬁned using restrained reﬁnement with TLS in the CCP4 supp
or mock-treated human sera to immobilized FcγRIIIa dete
(Supplementary Methods).majority of cellular FcγRs are therefore bound to IgG
Fc under physiological conditions. For example,
FcγRIIIa (Val158 variant) exhibits a Kd of around
0.1 μM for IgG1 Fc.14 Therefore, regardless of the
afﬁnity of an Fc for an FcγR, the limited availability
of unbound FcγR imposes an external constraint on
antibody effect or potency. While Fc engineering can
help overcome this effect for antigens expressed at
high levels on the cell surface,15 low-afﬁnity or low-
copy epitopes on infected or cancerous cells are
efﬁciently protected from ADCC by serumG. (a) Binding of human IgG1 Fc to immobilized FcγRIIIa
te-buffered saline) or increasing concentrations of human
e monoclonal Fab domain (Supplementary Methods). (b)
tructures of glycosylated human IgG Fcs using SHP17 by
g the second protomer free (pink ribbons; PDB IDs 1FC1,
NK, 3D03 and 3HKF). Broken lines are drawn between
lycosylated structures and indicate a displacement of
upplementary Methods) was concentrated to 7.0 mg/mL
drop vapor diffusion method18 using 100 nL protein plus
tals grew at room temperature in a precipitant containing
uffer (pH 4). Crystals were ﬂash frozen by immersion in a
(v/v) glycerol and then rapidly transferred to a gaseous
line I03 at Diamond Light Source, Oxfordshire, England.
CK,19 and the structure was solved using Phaser20 with
odel building was performed with Coot21 and iteratively
orted program REFMAC5.22 (c) Binding of EndoS-treated
rmined using an anti-human IgG secondary antibody
Table 1. Crystallographic data and reﬁnement statistics
for IgG1 FcGlcNAc
FcGlcNAc
Data collection
Beamline Diamond I03
Resolution (Å) 50.0–2.49 (2.59–2.49)a
Space group C2
Cell dimensions and angles
a, b, c (Å) 69.3, 110.9, 77.5
β, α, γ (°) 107.9, 90, 90
Wavelength (Å) 0.976
Unique reﬂections 19,399 (1923)
Completeness (%) 99.9 (99.9)
Rmerge (%)
b 0.108 (0.666)
I/σI 19.5 (2.2)
Average redundancy 8.4 (3.7)
Reﬁnement
Resolution range (Å) 34.3–2.49 (2.56–2.49)
Number of reﬂections 18,408 (1348)
Rwork (%)
c 19.5
Rfree (%)
d 23.4
r.m.s.d. bonds (Å) 0.008
r.m.s.d. angles (°) 1.2
Atoms per asymmetric unit
(protein/water/glycan)
3266/25/14
Average B-factors
(protein/water/glycan) (Å2)
77.3/60.9/104.0
Ramachandran plote
(favored/allowed) (%)
97.7/2.3
a Numbers in parentheses refer to the relevant outer-resolution
shell.
b Rmerge=∑hkl∑i|I(hkl;i)− 〈I(hkl)〉|/∑hkl∑iI(hkl;i), where I(hkl;i)
is the intensity of an individual measurement and 〈I(hkl)〉 is the
average intensity from multiple observations.
c Rwork=∑hkl||Fobs|−k|Fcalc||/∑hkl|Fobs|.
d Rfree is calculated as for Rwork, but using only 5% of the data
that were removed prior to reﬁnement.
e Ramachandran plots were calculated with MolProbity.28
3Antibody Receptor Refocusingimmunoglobulins.13,15,16 This leads to dosages of
clinical therapeutic antibody several orders of
magnitude greater than would be predicted by
serum-free assays.16
We designed an assay to replicate how mAb
binding to the FcγRIIIa receptor is affected by
human serum. In order to allow selective detection
of the engineered antibody Fc within an excess of
serum Fc domains, we constructed a chimeric
mAb containing the full human IgG1 Fc and a
murine Fab region (Supplementary Methods)
allowing detection with an anti-murine Fab sec-
ondary antibody (Fig. 1a). Consistent with previous
reports,13,15 even at extensive serum dilutions, mAb
binding was signiﬁcantly reduced, and at serum
concentrations approaching physiological levels,
mAb binding was barely detectable. Therefore, the
elimination of competing sAb represents a route to
the enhancement of mAb:FcγR interactions.
One solution in circumventing the inhibitory
effect of sAb is to selectively eliminate serum IgG
binding to FcγRs while leaving therapeutic mAb
function unperturbed. A number of bacterial
enzymes are able to interrupt Fc:FcγR
interactions.23 Notably, secreted endoglycosidases
are able to cleave the core GlcNAcβ1→4GlcNAc
linkage of the Fc glycan, release IgG from cellular
FcγRs and abrogate Fc-mediated effector
function.24–27 To elucidate the molecular basis of
IgG deactivation by endoglycosidases, we degly-
cosylated IgG1 Fc to a single GlcNAc moeity and
determined its structure by X-ray crystallographic
analysis to a resolution of 2.5 Å (Fig. 1b and Table
1 and Supplementary Methods and Fig. S1).
Comparison of this FcGlcNAc with known glyco-
sylated IgG Fc structures reveals that endoglyco-
sidase cleavage induces an inward movement of
the Cγ2 domains coupled with a rotation around
the central axis (Fig. 1b). This structural transfor-
mation displaces equivalent Cα atoms by up to
8 Å. By analogy with the conformation observed
in aglycosylated murine IgG Fc29 (Supplementary
Fig. 1), the fully closed quaternary structure
observed here is incompatible with known Fc:
FcγR interactions.30 This structure is consistent
with solution-phase NMR data that reveal signif-
icant changes in chemical shifts from the Cγ2
domain residues following endoglycosidase
cleavage.31 Similarly, displacement of the C'E
loop in our FcGlcNAc structure provides a plausible
explanation for the altered hydrogen/deuterium
exchange kinetics reported in this region following
deglycosylation.32 We also note that mutations
able to restore functionality to aglycosylated
antibodies include residues in the C'E loop.33
The change in conformation seen in our FcGlcNAc
structure also offers a structural basis for natural
immune evasion by a common human pathogen.
EndoS (endoglycosidase S), from Streptomycespyogenes, deglycosylates human IgG and decreases
FcγR binding of antibacterial antibodies,24–27 an
observation conﬁrmed here for FcγRIIIa (Fig. 1c).
The activity of this enzyme has also been
employed for therapeutic applications: EndoS is
under preclinical development as an immunosup-
pressive agent to diminish antibody-mediated
pathology via elimination of Fc:FcγR interactions
of autoimmune antibodies.34 However, we hy-
pothesized that EndoS could also be used to
enhance binding of mAbs to FcγR provided deacti-
vation was focused to bulk serum IgG and not to
recombinant mAb. This would require an engi-
neered antibody that maintains productive FcγR
binding with a carbohydrate component unaffect-
ed by EndoS.
The carbohydrate speciﬁcity of EndoS is not
known.35 However, consideration of its evolved
function suggested that commonly occurring IgG Fc
glycoforms would be efﬁciently hydrolyzed.26 By
contrast, it seemed less likely that EndoS would
have acquired activity against glycans not normally
4 Antibody Receptor Refocusingfound on human IgG. For example, oligomannose-
type structures are devoid of the terminal carbohy-
drate motifs typically present on antibody glycans
(principally, NeuNAcα2→6Gal, Galβ1→4GlcNAc
and GlcNAcβ1→2Man). Fortuitously, however,
oligomannose Fc glycoforms exhibit high-afﬁnity
binding to all human FcγRs14,36,37 and serum
clearance equivalent or slightly reduced38 compared
to complex-type glycoforms.
The ability of EndoS to hydrolyze either
naturally glycosylated IgG1 Fc or an engineered
Fc bearing oligomannose-type glycans was there-
fore determined. An advantage of the particular
Man5GlcNAc2 Fc glycoforms is that chemically
homogenous glycoproteins can be readily
manufactured at high yields through manipu-
lation of the mammalian glycan biosynthetic
pathway.37,39,40 Mass spectrometric analysis of
complex-type N-glycans, released from IgG1 Fc and
subsequently exposed to EndoS, showed complete
cleavage of the core GlcNAcβ1→4GlcNAc linkage
(Fig. 2a and b). In contrast, the oligomannose-Fig. 2. Resistance of oligomannose containing Fc glycofor
desorption/ionization mass spectrometry spectra of PNGase
deﬁcient HEK (human embryo kidney) 293S cells (Supple
respectively, Fc with complex-type (a–c) or oligomannose-ty
and d), EndoS (b and e) or EndoH (c and f). The spectra of
independent fucosylation.41 The cleavage of the core GlcNA
removal of a single GlcNAc (predicted Δm/z=203.1) or
representation of glycan structures follows that of Harvey et
position is shown by the angle of the lines linking the sug
horizontal line, 4-link; back slash, 6-link). Anomericity is in
lines for α-bonds.speciﬁc EndoH (endoglycosidase H) showed no
detectable hydrolysis (Fig. 2c). A reciprocal pattern
of speciﬁcities was observed for an engineered
oligomannose Fc glycoform that displayed com-
plete resistance to EndoS (Fig. 2d–f).
The enzymatic resistance of oligomannose-type
mAb provides a route to selective elimination of
natural antibody glycoforms from cellular FcγRs.
We therefore repeated our FcγR binding assay
using an oligomannose mAb glycoform, in the
presence of serum and EndoS, EndoH, both EndoS
and EndoH or no enzyme (Fig. 3a). Consistent
with the data from Fig. 1, the enzyme-free serum
efﬁciently blocked the binding of the oligoman-
nose-type mAb to FcγRIIIa. However, the addition
of EndoS led to a dramatic increase in apparent
afﬁnity of oligomannose mAb for FcγRIIIa with
50% receptor saturation achieved at approximately
0.05 μM mAb, a level approaching that of mAb:
FcγR determined for IgG in the complete absence
of serum and consistent with the reported value
(0.08 μM) of this interaction.4 This enhancementms to EndoS-mediated hydrolysis. Matrix-assisted laser
-F released N-glycans from IgG1 Fc expressed in GnT-I-
mentary Methods). These expression systems yielded,
pe (d–f) glycans, which were exposed to no enzyme (a
the oligomannose glycans reveal the presence of GnT-I-
cβ1→4GlcNAc bond by endoglycosidases results in the
Fucα1→6GlcNAc (predicted Δm/z=349.1). Symbolic
al.:42 ◊, Gal; ■, GlcNAc; ○, Man; , Fuc. The linkage
ar residues (vertical line, 2-link; forward slash, 3-link;
dicated by continuous lines for β-bonds and by broken
Fig. 3. EndoS-mediated deactivation of serum leads to enhancement of mAb binding to FcγRIIIa. (a) ELISA showing
the interaction between monoclonal IgG1 containing oligomannose (Man5GlcNAc2) glycans and immobilized FcγRIIIa in
the presence of PBS, serum, serum and EndoS, serum and EndoH or serum and EndoS and EndoH (Supplementary
Methods). Binding was detected using a secondary antibody speciﬁc for the monoclonal Fab domain as in Fig. 1a. Data
points represent the calculated mean of three independent measurements from a total of four experiments. (b) Schematic
illustration of the differential binding of FcγRIIIa to oligomannose and natural Fc glycoforms in the presence of EndoS.
Deactivated FcGlcNAc is shown in blue, and activated Fc in complex with FcγRIIIa (gray surface; PDB ID 1T83) is shown in
pink. Glycans are shown as yellow spheres.
5Antibody Receptor Refocusingwas a direct consequence of the differential glyco-
sylation of the engineered mAb and natural sAb.
This glycoform dependence was conﬁrmed by the
addition of EndoH, which led to loss of detectable
FcγRIIIa binding regardless of whether or not the
competing sera had also been treated with EndoS.
These data indicate that it is possible to selectively
target Fc receptors to IgGs with speciﬁc glycoforms
despite a large excess of competing serum Fc (Fig.
3b). The well-documented biological and pharma-
cological properties of both the oligomannose
glycoforms and the endoglycosidase enzymes
point toward the in vivo development of this
approach for almost any Fc:FcγR-dependent pro-
cess. Similarly, any EndoS-resistant antibodies
including aglycosylated mAbs engineered to exhibit
functional FcγR interactions33 could be employed.
An obvious additional application of mAbs, resis-
tant to IgG deactivating enzymes, would be in the
treatment of infections by bacteria, such as S.
pyogenes, which secrete these immune evasion
factors.
While mammalian glycosylation is heteroge-
neous, manipulation of cellular glycan biosynthesis
can yield chemically homogenous, precisely de-
ﬁned protein glycoforms. Similarly, despite cleav-
ing the same core GlcNAcβ1→4GlcNAc linkage
conserved in all N-linked glycans, endoglycosi-
dases have evolved a remarkable selectivity for
terminal carbohydrate motifs. In combination,
these tools allow for precise and independent
control of natural and engineered glycoproteins,
even in the complex biochemical environment of
human serum. Our strategy, which we termreceptor refocusing, provides a general approach
for boosting the immunological signal provided by
mAbs: by redirecting the cellular immune system
to a single antibody glycoform, which is in turn
directed to a single target antigen.Accession codes
Coordinates and structure factors of FcGlcNAc have
been deposited in the Protein Data Bank (PDB
accession number 4ACP).Acknowledgements
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